Past Issues – Page 126 – The Cancer Letter

Past issues are only available to subscribers. If you are not a member, click here to join.

NCI’s Intramural Spending is 17 Percent, Higher than 11.1 Percent NIH-Wide Level

NIH has launched a systematic examination of its intramural program, which accounts for 11.1 percent of its $30 billion budget.

The program was last examined in 1993, pursuant to a mandate from the House Appropriations Committee.

That examination was written by a panel co-chaired by Paul Marks, then president of Memorial Sloan-Kettering Cancer Center and Gail Cassell, then chair of the University of Alabama Department Microbiology.

	President Requests Extra $200 Mil for NIH President Barack Obama’s $3.9-trillion budget proposal for the 2015 fiscal year would bump NIH funding up to $30.2 billion—a $200 million increase over fiscal 2014—and would include an additional $8 million for NCI, totaling $4.931 billion for the institute.
	HPV Vaccines Should be Priority, says President’s Cancer Panel Human papillomavirus vaccines are underused in the U.S. and need to be made a national public health priority, according to a report from the President’s Cancer Panel. In a presentation to the National Cancer Advisory Board Feb. 27, panel chair Barbara Rimer outlined three goals to accelerate uptake of HPV vaccines, including having providers strongly encourage HPV vaccination to adolescents when other vaccines are being administered.
	NCI Publishes Report on Pancreatic Cancer NCI has issued a report detailing a “scientific framework” for advancing research on pancreatic ductal adenocarcinoma, indicating potential new funding opportunities for genomic studies for early detection of pancreatic cancer. The institute’s report is the result of the Recalcitrant Cancer Research Act, a bill proposed by the Pancreatic Cancer Action Network, and passed Jan. 2, 2013.
	In Brief Pasche named center director at Wake Forest Baptist Medical Center Jiali Han named Rachel Cecile Efroymson Professor in Cancer Research at the Indiana University Simon Cancer Center Carol Bier-Laning will lead CTCA Head and Neck Cancer Program Curie-Cancer renews partnership with DNA Therapeutics A correction

20140307 - Mar. 7, 2014

ISSUE 9 – FEB. 28, 2014

PDF

Groups Have No Budgets as NCTN Begins Work March 1

Two years ago, NCI officials made a promise to increase the budget of the cooperative groups program by $25.6 million.

The boost, which was approved by the NCI Board of Scientific Advisors, was part of an effort to revamp the groups inspired by a report from the Institute of Medicine.

On March 1, as the cooperative group program officially becomes the NCI National Clinical Trials Network, new money will not be a part of the transformation.

NCI National Lab’s Budget to Grow Over Its $299.2 Million FY2013 Level

The contractor running the Frederick National Laboratory for Cancer Research received nearly $300 million from NCI in the 2013 fiscal year, and is slated for an increase, officials said at a recent advisory committee meeting.

In Brief

Van Andel Research Institute to build epigenetics hub
Jennifer Doudna named winner of the Foundation for the NIH’s Lurie Prize
GRU Cancer Center receives $6 million committment
Twenty-six public health organizations call for retailers to stop selling tobacco products
ION Solutions selects Foundation Medicine for genomic profiling services
Mylan launches first Herceptin biosimilar
NeoGenomics launches profiling tests covering 22 cancer categories
Clarient adds BRAF diagnostic to its service offerings

20140228 - Feb. 28, 2014

ISSUE 8 – FEB. 21, 2014

PDF

NCI Launches M-PACT Next-Generation Trial As Group System Nears March 1 Transition

NCI has launched a pilot study to assess whether assigning cancer patients treatment based on the genetic characteristics of their disease can improve outcomes for patients with advanced metastatic solid tumors.

The Molecular Profiling based Assignment of Cancer Therapeutics, or M-PACT, trial is one of the first to use a randomized trial design to assign treatment based on specific mutations.

	NCI Clinical Trials Enrollment Drops to 17,500 Enrollment in NCI-sponsored National Clinical Trials Network clinical trials will drop to about 17,500 this fiscal year, the network groups have been told by NCI officials. This enrollment figure includes 3,600 pediatric patients, so the total adult enrollment will add up to about 14,000, insiders at cooperative groups say.
	GAO: FDA Data on Drug Shortages Inadequate FDA needs to improve its access to data if it is to manage drug shortages more effectively, the Government Accountability Office concluded. The FDA’s management of drug shortage data is “inconsistent with federal internal control standards,” the GAO report states.
	Duke’s Dzau Named IOM President Victor Dzau, chancellor of health affairs at Duke University and president and CEO of the Duke University Health System, was named president of the Institute of Medicine. Dzau will succeed current IOM president Harvey Fineberg effective July 1.
	In Brief NCI’s John Czajkowski to take executive dean position at Harvard Medical School Issam Markhoul named distinguished chair for hematology and oncology at University of Arkansas for Medical Sciences Margaret Dimond named president of Karmanos Cancer Hospital North Shore-LIJ Cancer Institute opens $47 million radiation facility Duke-NUS Graduate Medical School Singapore partners with ImaginAb Inc. St. Jude Thanks and Giving campaign rasies over $97 million Roswell Park Cancer Institute to collaborate with GenomOncology Roche Servicios S.A. and Cancer Genetics Inc. enter agreement Novartis acquires CoStim Pharmaceuticals Inc.

20140221 - Feb. 21, 2014

Page 126 of 131« First «...10 20 30 40 50 60 70 80 90 100...122 123 124 125126127 128 129 130 131 »